tbuckley/cabot-search huggingface dataset:
Cetuximab/irinotecan/5-FU +/-oxaliplatin or FOLFOXIRI +/- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study).
Authors: Gunnar Folprecht, Marika Mende, Torsten Liersch, Wolf Otto Bechstein, Claus-Henning Kohne, Alexander Stein, Volker Kunzmann, Michael Ghadimi, Ulf Peter Neumann, Sven Nilsson, Alexander Koenig, Ursula Pession, Achim Troja, Manfred Glados, Mathias Kleiss, Ulrike Ubbelohde, Juergen Weitz
Journal: Journal of Clinical Oncology (2020)

4024 Background: EGFR based combinations and the triplet combination FOLFOXIRI are known to increase response rates compared to doublet combinations. Methods: Patients with colorectal cancer and non-resectable liver metastases were enrolled into the trial. RAS wild type patients were randomised to cetuximab/FOLFIRI or cetuximab/FOLFOXIRI, RAS/BRAF mutant patients were randomised to FOLFOXIRI with or without bevacizumab. The primary endpoint was response. Secondary endpoints included progression free and overall survival. The trial was closed early due to poor recruitment. Results: Between 2014 and 2018, ninety-two pts were enrolled into the study. 54 wild type pts were randomised into cetuximab based treatment with (28 pts) or without (26 pts) oxaliplatin, 38 RAS/BRAF mutant pts were randomised to receive FOLFOXIRI alone (18 pts) or plus bevacizumab (16 pts). Objective response was achieved in 21/26 pts (81 % [95 CI: 61 – 93 %]) with cet/FOLFIRI, 24/28 pts (86 % [95 CI: 67 – 96 %]) with cet / FOLFOXIRI, 13/1 8 pts (72 % [95 CI: 46 – 90 %]) with FOLFOXIRI and 14/20 pts (70 % [95 CI: 46 – 88 %]) with bev/FOLFOXIRI. Two pts with cet/FOLFOXIRI and one pat with FOLFOXIRI achieved CR according to imaging. The median PFS was 12.7 [95 % CI: 7.2 – 18.2], 15.0 [95 % CI: 11.3 – 18.7], 17.5 [95 % CI: 8.0 – 27.1] and 15.0 [95 % CI: 11.4 – 18.5] months with cet/FOLFIRI, cet/FOLFOXIRI, FOLFOXIRI and bev/FOLFOXIRI. The median overall survival was 42 mo. [95 % CI: 28 – 55], 55 [95 % CI:41 – 68], 28 [95 % CI: 22 – 36] and 44 [95 % CI: 0 – 94] months with cet/FOLFIRI, cet/FOLFOXIRI, FOLFOXIRI and bev/FOLFOXIRI. The frequency of grade ≥ 3 toxicity per arm (cet/FOLFIRI, cet/FOLFOXIRI, FOLFOXIRI and bev/FOLFOXIRI) was 29 %, 46 %, 56 %. 45 % for neutropenia/leukopenia, 11 %, 12 %, 28 %, 25 % for diarrhea and 29 %, 19 %, 6 % and 5 % for skin toxicities. Conclusions: High response rates were observed in patients with colorectal liver metastases with all regimens. The numerically highest response rate was observed in RAS wild type patients treated with cetuximab/FOLFOXIRI. Clinical trial information: NCT01802645 .
北京市广安门外社区高龄老人健康状况的调查分析
Authors: 李宁燕, 姜鸥, 平光宇, 刘静
Journal: BMJ (2004)

北京市宣武区广安门外(广外)街道拥有十余万人口,老年人口占16.8%以上,其中≥80岁的高龄老人占≥60岁人口的10%.为了解高龄老人的健康状况,提高老年人健康水平,并为社区卫生服务建设提供参考意见,我们于2001年对该区高龄老人进行了健康状况的调查研究。
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Authors: Saad Z Usmani, Hareth Nahi, Torben Plesner, Brendan M Weiss, Nizar J Bahlis, Andrew Belch, Peter M Voorhees, Jacob P Laubach, Niels W C J van de Donk, Tahamtan Ahmadi, Clarissa M Uhlar, Jianping Wang, Huaibao Feng, Ming Qi, Paul G Richardson, Sagar Lonial
Journal: The Lancet Haematology (2020)
Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).
Authors: Jayesh Desai, Jie Wang, Qing Zhou, Jun Zhao, Sanjeev Deva, Wei Tan, Xiaopeng Ma, Yun Zhang, Zhirong Shen, Xikun Wu, Shiangjiin Leaw, Yanjie Wu, Yi-Long Wu
Journal: Journal of Clinical Oncology (2020)

e15258 Background: Tislelizumab, an anti-PD-1 monoclonal antibody, showed clinical benefit for patients (pts) with NSCLC alone (NCT02407990, CTR20160872) and in combination with chemotherapy (NCT03432598). Gene expression profiles (GEP) associated with response and resistance to tislelizumab in these studies were assessed. Methods: The GEP of baseline tumor samples from 59 nonsquamous (NSQ) and 42 squamous (SQ) NSCLC pts treated with tislelizumab monotherapy (mono) as ≥1L treatment, and 16 NSQ and 21 SQ pts treated with tislelizumab plus chemotherapy (combo) as 1L treatment were assessed using the 1392-gene HTG GEP EdgeSeq panel. NSQ and SQ cohorts were analyzed separately due to distinct GEP features shown by PCA and t-SNE clustering. Results: Tislelizumab mono and combo showed antitumor activity in NSCLC (Table). In 80 biomarker-evaluable samples, inflamed tumor signatures (inflammatory GEP; antigen presentation GEP) were associated with longer overall survival (log-rank test, NSQ mono: P=0.04, 0.003; NSQ combo: P=0.05, 0.02; SQ combo: P=0.06, 0.06). Monotherapy non-responders (NRs) were clustered into 2 subgroups (NR1, NR2) with distinct GEPs. Compared with responders, NR1 had proliferation signatures (elevated cell cycle [CC] and DNA repair) in both NSQ ( P=0.2, 0.02) and SQ ( P=0.03, 0.4) cohorts, trending toward low inflamed tumor signatures. In NR pts receiving combo, CC and DNA repair signatures were not enriched, and high CC and DNA repair scores were observed in some SQ combo responders versus NRs ( P=0.2, 0.02). NR2 had higher M2 macrophage and Treg cell signatures versus responders in both NSQ and SQ mono, despite high inflamed tumor and low proliferation signatures. NR2 also had increased expression of genes related to immune regulation and angiogenesis, including PIK3CD, CCR2, CD244, IRAK3, and MAP4K1 ( P&lt;0.05) in NSQ, and PIK3CD, CCR2, CD40, CD163, MMP12, VEGFC, and TEK ( P&lt;0.05) in SQ. Conclusions: Clinical benefit in pts with NSCLC receiving tislelizumab (mono or combo) was associated with high inflamed tumor signatures, while elevated immune suppressive cell signatures may indicate resistance. High proliferation signatures were associated with resistance to monotherapy, but not to combination therapy. Both immune- and tumor-intrinsic factors may be considered for validation in future clinical trials. [Table: see text]
Lungs and abdominal infection complicated by acute pulmonary embolism with lower limb venous thrombosis: report of one case
Authors: Xu Li, Guijie Xin, Weihua Zhang, Xiaolin Guo, Pujun Gao, Wang Lu, Yulin Hu
Journal: BMJ (2016)

急性肺栓塞起病急，临床表现不典型，病情发展迅速，死亡率较高。有报道提出感染可能是该病诱因。报道1例因肺内及腹腔感染入院，诊治过程中并发急性肺栓塞和下肢静脉血栓患者的病例资料及诊治经过。
Characterizing physiological and symptomatic variation in menstrual cycles using self-tracked mobile-health data
Authors: Kathy Li, Iñigo Urteaga, Chris H. Wiggins, Anna Druet, Amanda Shea, Virginia J. Vitzthum, Noémie Elhadad
Journal: npj Digital Medicine (2020)

The menstrual cycle is a key indicator of overall health for women of reproductive age. Previously, menstruation was primarily studied through survey results; however, as menstrual tracking mobile apps become more widely adopted, they provide an increasingly large, content-rich source of menstrual health experiences and behaviors over time. By exploring a database of user-tracked observations from the Clue app by BioWink GmbH of over 378,000 users and 4.9 million natural cycles, we show that self-reported menstrual tracker data can reveal statistically significant relationships between per-person cycle length variability and self-reported qualitative symptoms. A concern for self-tracked data is that they reflect not only physiological behaviors, but also the engagement dynamics of app users. To mitigate such potential artifacts, we develop a procedure to exclude cycles lacking user engagement, thereby allowing us to better distinguish true menstrual patterns from tracking anomalies. We uncover that women located at different ends of the menstrual variability spectrum, based on the consistency of their cycle length statistics, exhibit statistically significant differences in their cycle characteristics and symptom tracking patterns. We also find that cycle and period length statistics are stationary over the app usage timeline across the variability spectrum. The symptoms that we identify as showing statistically significant association with timing data can be useful to clinicians and users for predicting cycle variability from symptoms, or as potential health indicators for conditions like endometriosis. Our findings showcase the potential of longitudinal, high-resolution self-tracked data to improve understanding of menstruation and women's health as a whole.
Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer.
Authors: Joelle Soriano, Katrina Hueniken, Jaspreet K. Bajwa, George Dong, Wanning Wang, Tyler Soberano, Kirsty Taylor, M. Catherine Brown, Eric Xueyu Chen, Jennifer J. Knox, Raymond Woo-Jun Jang, Rebecca Wong, Gail Elizabeth Darling, Wei Xu, Elena Elimova, Geoffrey Liu, Dmitry Rozenberg, Micheal McInnis, Aline Fusco Fares
Journal: Journal of Clinical Oncology (2020)

4544 Background: Body fat and muscle influence prognosis in many cancer types. However, this association is unclear for real-world MEC pts, who are often in worse performance status than their previous baseline. In addition, the relationship of BM at presentation and QoL is unknown. We used real-world MEC pts to assess the importance of BM in OS and QoL. Methods: BM were done at baseline computed tomography in MEC pts, treated from 2006-2014 at the Princess Margaret Cancer Centre. Two radiologists (correlation 0.9-1.0) assessed L3 level using SliceOMatic to determine Skeletal Muscle Index (SMI - muscle area at L3 normalized by height), Visceral Adiposity Tissue (VAT), and Subcutaneous Adiposity Tissue (SAT). We used previously published cut-offs for sarcopenia based on sex and BMI, and the highest tertile as the cut-off for adiposity. We used prospectively collected QoL surveys including EuroQol 5D-5L (EQ5D) and the Functional Assessment of Cancer Therapy – Esophageal (FACT-E). Results: Of 200 pts, 164 (82%) were male, 180 (92%) were non-Asian; mean age was 62 y; ECOG: 0-1 = 142 (71%), 2 = 58 (29%); 69% had adenocarcinoma; 5% were underweight, 44% normal weight, 30% overweight, and 21% obese. 40 (20%) pts completed QoL measures. We found that 104 (52%) were sarcopenic at baseline, 66 (33%) had high VAT, and 67 (34%) had high SAT. A multivariable Cox model showed that sarcopenia and VAT were independent prognostic variables for three-year OS: sarcopenia increased the risk of death by 50% (adjusted hazard ratio, aHR 1.50, p 0.02), whereas every 100-cm 2 increase in VAT improved OS by 24% (aHR 0.76, p 0.03). Finally, sarcopenic pts had significantly worse physical well-being (p 0.01) on FACT-E after adjusting for sex and age. Numerically, the EQ5D also showed lower scores in sarcopenic pts but this was not statistically significant (p 0.18). Conclusions: In MEC pts, sarcopenia and low visceral adiposity result in worse OS; sarcopenia is also significantly associated with poor QoL. Future work will need to focus on potential rehabilitation strategies such as nutritional support and exercise training to offset the poor prognosis associated with sarcopenia and reduced adiposity. [Table: see text]
Incidence and risk of colitis with programmed death-1 versus programmed death-ligand 1 inhibitors for the treatment of cancer.
Authors: Hirotaka Miyashita, Takahisa Mikami, Sera Satoi, Christina Cruz, Matt D. Galsky
Journal: Journal of Clinical Oncology (2020)

e15087 Background: Programmed death 1 (PD-1) inhibitors and Programmed Death-Ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) approved for treatment of several different cancers. Colitis is a major immune-related adverse event associated with ICIs, but the risk of colitis with PD-1 versus PD-L1 inhibitors is not well characterized. Methods: We performed a meta-analysis for the incidence of all grade and grade 3-4 colitis with PD-1 inhibitor (nivolumab, pembrolizumab, and cemiplimab) or PD-L1 inhibitor (atezolizumab, avelumab, and durvalumab) monotherapy using a fixed effects model. We also conducted subgroup meta-analyses of non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) trials, and a network meta-analysis of randomized trials comparing PD-1 or PD-L1 inhibitors with docetaxel for NSCLC. We analyzed Food and Drug Administration Adverse Event Reporting System (FAERS) database to estimate the reporting odds ratio (ROR) of each medication, which provides the estimated relative risk most valid in spontaneous report database. Results: We identified 88 studies that met inclusion for the analysis. PD-1 inhibitors were associated with higher incidence of all grade and grade 3-4 colitis compared to PD-L1 inhibitors in the analysis of all cancer types (1.49% vs 0.83%, relative risk (RR); 1.80, 95% confidence interval (CI); 1.22-2.67 for all grade colitis, and 0.85% vs 0.34%, RR; 2.52, 95% CI; 1.46-4.37 for grade 3-4 colitis). The meta-analyses on NSCLC and UC, and the network meta-analysis on NSCLC also showed the tendency that PD-1 inhibitors are associated with higher risk of all grade and grade 3-4 colitis, though only the analysis on UC for all grade colitis showed a significant difference. (1.95% vs 0.64%, RR; 3.05, 95% CI; 1.18 - 7.88) Retrospective analysis showed ROR of 16.78 (95% CI; 15.8-17.8) for PD-1 inhibitors, and 12.93 (95% CI; 10.74-15.42) for PD-L1 inhibitors. We found that ROR of PD-1inhibitors was 1.17 (95% CI; 0.97-1.43) compared to PD-L1 inhibitors. Conclusions: Our study showed that PD-1 inhibitors have higher risk of colitis than PD-L1 inhibitors.
The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).
Authors: Piotr Rutkowski, Marcin Zietek, Bozena Cybulska-Stopa, Joanna Streb, Stanislaw Gluszek, Michał Jankowski, Karolina Lopacka-Szatan, Manuela Las-Jankowska, Piotr Hudziec, Anna Klimczak, Tomasz Olesinski, Tomasz Switaj, Hanna Kosela-Paterczyk, Elzbieta Bylina, Czeslaw Osuch
Journal: Journal of Clinical Oncology (2020)

e23524 Background: The real-world data on outcomes of adjuvant therapy in high-risk gastrointestinal stromal tumors (GIST) are very limited. Methods: We have analyzed the data of 107 consecutive patients (52 male, 56 female) with GIST after resection treated with adjuvant imatinib (for planned 3 years with initial dose 400 mg daily, started not later than 4 months after operation) in 6 oncological centers in 2013-2018. All patients were required to have high risk of recurrence (at least 50% according to NCCN/AFIP criteria), known mutational status to exclude PDGFRA D842V mutants and KIT/PDGFRA-wild type cases from therapy. Median follow-up time was 24 months. Results: The most common primary localization of GIST was small bowel (63 patients; 59%), followed by the stomach (40 patients; 37%). The majority of GIST cases harbored exon 11 KIT mutations (88 cases, 82%), 11 cases had exon 9 KIT mutations (10%), 8 had other KIT/PDGFRA mutations potentially sensitive to imatinib. Thirty three patients (31%) finished 3-year adjuvant imatinib therapy as planned, 59 (55%) still continue therapy, 4 (4%) patients had finished adjuvant therapy prematurely due to toxicity, 6 (6%) due to disease progression on treatment and 5 (4%) due to other reasons. The disease relapse was detected in 16 patients, of them in 4 cases in exon 9 KIT mutants (36%), and 10 cases in patients with exon 11 KIT mutations (11%) [p &lt; 0.05]. Estimated 4-year relapse-free survival (RFS) rate is 78%. Conclusions: The early results of adjuvant therapy with imatinib in routine practice outside clinical trials in high-risk mutation-drive GIST patients only confirm high efficacy of this therapy with better tolerability than in clinical trials. Moreover, overrepresentation of exon 9 KIT mutants in a group of patients with disease relapse may indicate that standard 400 mg dose in adjuvant treatment is not sufficient for prevention of disease relapse.
Prevention and treatment for chronic hepatitis B: interpretation of Chinese guideline (2015 version)
Authors: Xuefei Duan
Journal: BMJ (2016)

2015年10月发布的《慢性乙型肝炎防治指南》是中华医学会肝病学分会和感染病学分会为规范慢性乙型肝炎的预防、诊断和抗病毒治疗而制定的最新指南。它首次提出了临床治愈的治疗目标，强调一线药物治疗，并对特殊慢性乙型肝炎人群给予高度关注。本文就指南中与基层医生密切相关的要点进行解读，以期提高基层医生对慢性乙型肝炎的防治水平。
Correction: Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
Authors: Charalambos Kaittanis, Chrysafis Andreou, Haley Hieronymus, Ninghui Mao, Catherine A. Foss, Matthias Eiber, Gregor Weirich, Palak Panchal, Anuradha Gopalan, Juan Zurita, Samuel Achilefu, Gabriela Chiosis, Vladimir Ponomarev, Markus Schwaiger, Brett S. Carver, Martin G. Pomper, Jan Grimm
Journal: The Journal of Experimental Medicine (2017)
甲状旁腺机能亢进性肌病合并甲状腺机能亢进一例
Authors: 万琦, 诸兴明
Journal: BMJ (2011)

患者男性,24岁,未婚,工人.因进行性双下肢乏力伴肌肉酸痛2月余,于2009年7月2日入院.患者从5月份起出现逐渐加重的双下肢乏力症状,伴腿部肌肉发胀感,两侧髋部酸痛不适,6月初已发展到行走步态明显异常,下蹲后无法自行站起.6月中旬在当地医院检查,甲状腺功能正常,血钙3.11mmol/L(正常值2.1～2.6 mmol/L),血钾正常;新斯的明试验阴性。
Prevalence of herpes simplex virus I, II, cytomegalovirus, Epstein–Barr virus and human papillomavirus (6, 11, 16 and 18) in normal oral mucosa and OSCC patients in Saint-Petersburg (Russia).
Authors: Svetlana Kutukova, Natalia P. Beliak, Julia V. Ivaskova, Alexey B. Chuhlovin, Andrey I. Yaremenko, Tatiana S. Ermakova
Journal: Journal of Clinical Oncology (2020)

e18539 Background: The objective of our study was to evaluate the prevalence of DNA of HSV I, II, CMV, EBV, HPV6.11, HPV16, HPV18 in normal oral mucosa and oral squamous cell carcinoma (OSCC), and determine this association with long-term treatment outcomes and patient survival. Methods: The study included 116 patients with OSCC (stage I-IVB who received standard treatment) and 50 healthy volunteers, median age 60.0 yrs (95% CI 58.0-64.0). Using real-time PCR (polymerase chain reaction), freshlyfrozen samples of the tumor and normal mucous membranes of the cavity were analyzed. mouths, which, after collection, were placed in an EDTA solution and frozen at 20°C. Results: In 54 (46.55%) OSCC and 17 (34.00%) normal mucous viral DNA was not found (p = 0.13). The occurrence of DNA (OSCC vs. normal) of the following viruses was the same in both OSCC and normal mucosa: HSV I, II: 2 (1.72%) vs. 2 (4.00%) (p = 0.38); EBV: 40 (34.48%) vs. 15 (30.00%) (p = 0.57); CMV: 5 (4.31%) vs. 2 (4.00%) (p = 0.93); HPV6.11: 16 (13.79%) vs. 6 (15.00%) (p = 0.84); HPV16: 12 (10.34%) vs. 2 (4.00%) (p = 0.18). HPV18 DNA: 20 (17.24%) vs. 24 (48.0%) (p &lt;0.0001) was found significantly less frequently in the OSCC group. In addition, EBV + HPV18: 7 (14.00%) vs. 5 (4.31%) (p = 0.0270) was more common vs. OSCC in the group of healthy volunteers; CMV + HPV18: 2 (4.00%) vs. 0 (p = 0.0302). In the OSCC group, patients with stage III disease were more often virus-positive (p = 0.0137); the pterygo-maxillary fold region (p = 0.0438); with partial keratinization of cells (p = 0.05). PFS in the HPV18 (+) OSCC group was 38.5 months (95% CI 11.00-66.0) and 23.5 m higher than the group of HPV18 (-) patients (HR = 0.63; 95% CI 0.39-1.03; p = 0.0399). In virus-negative patients, PD was more often recorded: 12 (24.00%) vs. 2 (3.03%) (p = 0.0006). In the group of virus-positive patients, OS and PFS, even with non-radical treatment, were significantly higher than virus-negative patients with radical treatment. OS: vir (+)/non-radical = 69.0 mo vs. vir (-)/radical = 15.0 mo (HR = 0.22; 95% CI 0.11-0.47; p &lt;0.0001). PFS: vir (+)/non-radical = 56.0 mo vs. vir (-)/radical = 11.0 mo (HR = 0.20; 95% CI 0.09-0.45; p &lt;0.0001). Conclusions: The association of OSCC with viral DNA, especially HPV18, is a favorable prognosis of the disease and a longer OS and PFS, even when radical treatment is not possible.
Ultrasound or CT-guided percutaneous core needle biopsy in diagnosis of small renal masses
Authors: Ying Liu, Qi-zhong Fu, Tai-yi Jin, Sheng-fang Dong, Jian-xun Yang, Guang-yao L
Journal: BMJ (2012)

Eighty six patients with renal masses≤4.0 cm underwent ultrasound or CT-guided core needle biopsies.The clinical data including the initial biopsy technique,pathologic findings,and the clinical outcome were retrospectively reviewed. Biopsies were failed for diagnosis in 6 cases ( 7％ ) because of necrosis or hemorrhage of the tissue specimens.Of 80 successful biopsies,52 cases (65％) were diagnosed as malignant tumor and 28 cases (35％) as benign. Five patients had biopsy complications (6％),including postoperative hypotension,hemouria and perirenal hematoma. Forty-seven patients underwent surgical extirpation ; the consistency rate of histopathological diagnosis between biopsy and surgical specimens was 100％ in these patients.The results indicate that ultrasound or CT-guided core needle biopsy is an effective and safe procedure for diagnosis of renal small masses.

Key words: 
Biopsy,needle; Kidney neoplasms
US to withdraw from WHO as China has “total control” over it, Trump claims
Authors: Elisabeth Mahase
Journal: BMJ (2020)

The US will withdraw from the World Health Organization, according to the country’s president, who has claimed that China had “total control” over it.

Donald Trump gave an ultimatum to director general Tedros Ghebreyesus on 18 May1 saying that if WHO did not “commit to major substantive improvements within the next 30 days” he would permanently freeze US funding to the UN health agency and reconsider its membership.

Speaking on 29 May, Trump said WHO had “refused to act” and as such he would be “terminating” the relationship and redirecting funds to other “urgent global public health needs.”

Health leaders have criticised the decision to withdraw, suggesting that it is being used as a distraction from the situation in the US. The country has had over 100 000 covid-19 related deaths and more than 1.8m cases.2

They have also pointed out …
Inside-out versus transobturator-tape in the surgical management of female stress urinary incontinence: a meta-analysis of effectiveness and complications
Authors: Quan Zhou, Yan-feng Song, Long-hua Luo, Shui-xiu Fan
Journal: BMJ (2013)

To assess the effectiveness and safety of inside-out (TVT-O) vs. outside-in transobturator-tape procedures (TOT) in the surgical management of female stress urinary incontinence (SUI). A total of 8 randomized controlled trials were retrieved from the literature and analyzed by meta-analysis with RevMan 5.0 software. Meta-analysis showed that no statistical differences existed in objective cure rate, objective failure, postoperative voiding dysfunction, groin/thigh pain and sling exposure in both procedures (P>0.05). These preliminary results suggest there is no evidence of significant differences in the efficacy and safety between TVT-O and TOT.


Key words: 
Urinary incontinence, stress; Gynecologic surgical procedures